中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.022 seconds)

    METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY
    11.
    发明申请
    METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY 审中-公开
    评估同种异体重建缺陷的方法和材料

    公开(公告)号：US20140363521A1

    公开(公告)日：2014-12-11

    申请号：US14245576

    申请日：2014-04-04

    Applicant: Myriad Genetics, Inc.

    Inventor： Victor Abkevich ,  Kirsten Timms ,  Alexander Gutin

    IPC: C12Q1/68 ,  A61K33/24 ,  G06F19/18

    CPC classification number: C12Q1/6886 ,  A61K33/24 ,  C12Q1/6827 ,  C12Q1/6858 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156 ,  G16B20/00 ,  C12Q2535/122 ,  C12Q2537/143

    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

    Abstract translation: 本文件提供了评估样品（例如癌细胞）中存在同源重组缺陷（HRD）或HRD标记的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否包含HRD特征的方法和材料。 还提供了用于鉴别具有同源性定向修复（HDR）缺陷的细胞（例如癌细胞）的材料和方法以及用于鉴定可能对特定癌症治疗方案作出反应的癌症患者的材料和方法。

    Method of treating cancer
    14.
    发明授权
    Method of treating cancer 有权

    公开(公告)号：US11174519B2

    公开(公告)日：2021-11-16

    申请号：US16691480

    申请日：2019-11-21

    Applicant: MYRIAD GENETICS, INC.

    Inventor： Victor Abkevich ,  Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

    IPC: C12Q1/6886 ,  C12Q1/6827 ,  G16B20/00 ,  G16H20/00 ,  G16B20/20 ,  G16B20/10

    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

    Method for treating cancer
    15.
    发明授权
    Method for treating cancer 有权

    公开(公告)号：US10851425B2

    公开(公告)日：2020-12-01

    申请号：US16576643

    申请日：2019-09-19

    Applicant: MYRIAD GENETICS, INC.

    Inventor： Victor Abkevich ,  Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

    IPC: C12Q1/6886 ,  C12Q1/6827 ,  G16B20/00

    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

    Methods and materials for assessing homologous recombination deficiency
    16.
    发明授权
    Methods and materials for assessing homologous recombination deficiency 有权

    公开(公告)号：US10400287B2

    公开(公告)日：2019-09-03

    申请号：US15433249

    申请日：2017-02-15

    Applicant: Myriad Genetics, Inc.

    Inventor： Victor Abkevich ,  Kirsten Timms ,  Alexander Gutin ,  Julia Reid

    IPC: C12Q1/68 ,  C12Q1/6886

    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

    METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
    18.
    发明申请
    METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY 审中-公开
    用于评估异常性损失的方法和材料

    公开(公告)号：US20150080260A1

    公开(公告)日：2015-03-19

    申请号：US14554715

    申请日：2014-11-26

    Applicant: Myriad Genetics, Inc.

    Inventor： Victor Abkevich ,  Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q1/6827 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G16B20/00 ,  C12Q2537/16

    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

    Abstract translation: 本文件提供了评估样品（例如癌细胞）中存在杂合性（LOH）特征丧失的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否包含LOH标记的方法和材料。 还提供了用于鉴别具有同源性定向修复（HDR）缺陷的细胞（例如癌细胞）的材料和方法以及用于鉴定可能对特定癌症治疗方案作出反应的癌症患者的材料和方法。

    Methods and materials for assessing homologous recombination deficiency
    20.
    发明授权
    Methods and materials for assessing homologous recombination deficiency 有权

    公开(公告)号：US12221656B2

    公开(公告)日：2025-02-11

    申请号：US18081603

    申请日：2022-12-14

    Applicant: Myriad Genetics, Inc.

    Inventor： Victor Abkevich ,  Kirsten Timms ,  Alexander Gutin ,  Julia Reid

    IPC: C12Q1/6886

    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Patent Agency Ranking